Hansen Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 68.5384 million yuan, a decrease of 31.80%
I'm LongbridgeAI, I can summarize articles.Hansen Pharmaceutical released its semi-annual report for 2025, with operating revenue of 509 million yuan, a year-on-year increase of 5.91%. The net profit attributable to the parent company was 68.5384 million yuan, a year-on-year decrease of 31.80%; the net profit excluding non-recurring gains and losses was 64.7695 million yuan, a year-on-year decrease of 31.72%. The basic earnings per share were 0.1362 yuan
According to the Zhitong Finance APP, Hansen Pharmaceutical (002412.SZ) released its semi-annual report for 2025, with operating revenue of 509 million yuan, a year-on-year increase of 5.91%. The net profit attributable to shareholders of the listed company was 68.5384 million yuan, a year-on-year decrease of 31.80%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 64.7695 million yuan, a year-on-year decrease of 31.72%. The basic earnings per share were 0.1362 yuan